Nao Suzuki

TL;DR: The ovarian fragmentation–in vitro activation approach is not only valuable for treating infertility of POI patients but could also be useful for middle-aged infertile women, cancer patients undergoing sterilizing treatments, and other conditions of diminished ovarian reserve.

TL;DR: The found that routine histological analyses of ovarian cortices and shorter duration from initial POI diagnosis to ovariectomy are valid parameters for predicting IVA success, and the present vitrification protocol is effective for ovarian tissue cryopreservation.

TL;DR: The results identified a number of themes for improving MOC in each domain, which included: the importance of patients receiving communication that is of a higher quality and in different formats on their fertility risk and FP options; improving provision of oncofertility care in a timely manner; improving access to age-appropriate care; defining the role and scope of practice of all H CPs; and improving communication between different HCPs.

TL;DR: No significant survival benefit was found for CPT-P in patients with CCC, and both regimens were well tolerated, but the toxicity profiles differed significantly.

TL;DR: The fourth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer was published in 2015 and contained seven chapters and six flow charts.